Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
#What Are The Current (2025) And Forecast (2029) Sizes Of The Acute Care Syndromic Testing Market?
The market for acute care syndromic testing has experienced swift expansion lately, projected to climb from a valuation of $4.08 billion in 2024 to $4.59 billion by 2025, showcasing a compound annual growth rate (CAGR) amounting to 12.3%. This upward trajectory during the past period stems from several contributing factors, including heightened consciousness regarding antimicrobial resistance, an upswing in governmental financial support directed towards infectious disease initiatives, augmented investment flowing into healthcare facilities, a greater emphasis placed on syndromic testing methodologies, the broader adoption of telemedicine, and an overall increase in the incidence of infectious diseases.
Anticipated within the upcoming years is substantial expansion for the acute care syndromic testing sector; by the year 2029, its valuation is projected to reach $7.39 billion, achieving a compound annual growth rate (CAGR) of 12.7%, with this upward trajectory being fueled by several key factors, including the increasing incidence of infectious ailments, a heightened need for expedited diagnostic methods, the broadening scope of medical services offered, increased deployment of syndromic panels capable of simultaneous testing, and the aging demographic bulge. Furthermore, the forthcoming period is set to be characterized by significant shifts such as a move towards diagnostics administered at the point of care, the incorporation of web-based infrastructures, wider acceptance of multi-analyte panels, advancements in artificial intelligence integrated tools, and greater automation within the testing protocols themselves.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp
What Are The Main Drivers Boosting The Acute Care Syndromic Testing Industry’s Expansion?
The expanding prevalence of communicable ailments is anticipated to boost the market for acute care syndromic testing moving ahead. These infections, stemming from detrimental microbes like bacteria, viruses, fungi, or parasites that transfer between individuals, creatures, or the surroundings, are becoming more frequent due to elements such as demographic increase, city expansion, international movement, resistance to antimicrobials, and shifts in climate, thus heightening the demand for successful prophylaxis and therapy. Acute care syndromic analysis plays a crucial role in managing these health threats by swiftly pinpointing causal agents and concurrent infections leveraging panels of molecular diagnostic tests, which consequently facilitates prompt, focused therapeutic strategy implementation. As an illustration, data released by the UK’s Health Security Agency in February 2024 revealed that for the fourth week of 2024, the confirmed rate of influenza positivity climbed to 16.6%, a step up from the 14.0% recorded the week immediately preceding it; similarly, consultations related to influenza-like illness (ILI) saw an uptick, registering 9.8 per 100,000 individuals versus the 7.5 per 100,000 reported in the earlier week, while influenza-related hospital admissions also escalated, moving to 7.63 per 100,000 from the previous week’s figure of 5.12 per 100,000. Consequently, the rising tide of infectious diseases serves as a significant impetus for the growth of the acute care syndromic testing sector.
What Are The Key Segments In The Acute Care Syndromic Testing Market?
The acute care syndromic testingmarket covered in this report is segmented –
1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types
2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types
3) By Target: Bacteria, Viruses, Fungi, Parasites
4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users
Subsegments:
1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases
2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases
3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases
4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases
5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases
Which Market Trends Are Creating New Opportunities In The Acute Care Syndromic Testing Industry?
Leading firms within the acute care syndromic testing sector are concentrating efforts on refining existing technologies, notably multiplexed real-time polymerase chain reaction (PCR), with the objectives of boosting diagnostic precision, facilitating swift identification of disease agents, optimizing laboratory operational efficiency, decreasing the time needed to receive results, and ultimately, yielding superior patient results via highly accurate and prompt therapeutic actions.This sophisticated molecular diagnostic approach, known as multiplex real-time PCR, allows for the simultaneous identification and measurement of numerous infectious agents or genetic markers within one PCR run, thereby boosting both the efficiency and exactness of disease identification processes.To illustrate this development, in April of 2023, QIAGEN N.V., a biotechnology firm headquartered in the Netherlands, introduced its QIAstat-Dx syndromic testing platform across Japan, which incorporates a respiratory panel capable of identifying more than twenty distinct pathogens sourced from just one patient specimen, achieving fast outcomes with considerably less effort than employing separate, singular PCR analyses.As of the close of 2022, this system had seen worldwide deployment, exceeding 3,500 installed units, assisting clinicians in diagnosing illnesses affecting the respiratory system, the gastrointestinal tract, and those related to meningitis, with the platform now accessible in more than a hundred nations, significantly broadening the global reach of syndromic testing capabilities.
Which Leading Players Are Enhancing Their Acute Care Syndromic Testing Market Presence Worldwide?
Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report
What Are The Regional Market Dynamics Impacting The Acute Care Syndromic Testing Industry?
North America was the largest region in the acute care syndromic testing market in 2024. The regions covered in the acute care syndromic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Acute Care Syndromic Testing Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21078&type=smp
Browse Through More Reports Similar to the Global Acute Care Syndromic Testing Market 2025, By The Business Research Company
Post Acute Care Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/post-acute-care-global-market-report
Autoimmune Disease Diagnosis Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report
Acute Ischemic Stroke Diagnosis Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model